Teladoc Health (NYSE:TDOC) Releases Earnings Results, Beats Expectations By $0.07 EPS

Teladoc Health (NYSE:TDOC) issued its earnings results on Wednesday. The health services provider reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07, FiscalAI reports. The business had revenue of $605.10 million for the quarter, compared to the consensus estimate of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.52%. The business’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.28) earnings per share.

Here are the key takeaways from Teladoc Health’s conference call:

• Third-quarter results exceeded expectations: Revenue was $605 million, near the high end of guidance, while adjusted EBITDA rose 13.5% year over year to $79 million, with margin expanding to 13.1%.
• Integrated Care delivered 2.3% revenue growth and an 18.8% adjusted EBITDA margin, supported by double-digit international growth, higher chronic-care enrollment, and productivity improvements. The company raised its full-year Integrated Care margin outlook to 16.0%-16.6%.
• BetterHelp’s insurance transition is gaining traction, with insurance revenue reaching $32 million, weekly insurance-covered sessions rising to 27,000, and more than 11,000 credentialed therapists. Management is targeting an annualized insurance revenue run rate of at least $200 million exiting 2027.
• BetterHelp’s overall revenue declined 12.8% year over year as cash-pay demand remained pressured, and management expects continued cash-pay weakness as advertising spending is reduced further. Full-year BetterHelp revenue is now expected to decline 12.9%-16.1% from 2025, with lower margins due to insurance mix and related investments.
• Teladoc One and the Teledine Health acquisition are intended to expand comprehensive virtual care and U.S. hospital hybrid-care opportunities, but broader Teladoc One availability is not expected until 2027. The company also plans to address the $1 billion convertible-note maturity through potential debt financing, cash, and note repurchases, subject to market conditions.

Teladoc Health Trading Down 1.2%

NYSE TDOC traded down $0.10 on Friday, hitting $8.62. 1,291,268 shares of the company were exchanged, compared to its average volume of 5,078,036. The company has a market cap of $1.57 billion, a P/E ratio of -9.95 and a beta of 2.14. The firm has a 50 day moving average of $6.19 and a two-hundred day moving average of $6.47. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TDOC. Canaccord Genuity Group dropped their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Stifel Nicolaus raised their target price on shares of Teladoc Health from $5.50 to $6.50 and gave the company a “hold” rating in a research note on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a report on Thursday. Citigroup dropped their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research report on Monday, August 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $7.54.

Insider Activity

In other Teladoc Health news, CEO Charles III sold 17,805 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the transaction, the chief executive officer directly owned 465,535 shares of the company’s stock, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company’s stock.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported third-quarter revenue of $605.1 million, ahead of the approximately $588 million consensus estimate, while its $0.15 per-share loss was narrower than the expected $0.22 loss. Revenue still declined about 3% year over year, but the results exceeded expectations. Teladoc Health Reports Third Quarter 2026 Results
• Positive Sentiment: Adjusted EBITDA reached approximately $79 million, near the high end of management’s prior outlook, and cash-flow improvement made the quarterly loss appear higher quality to investors. Teladoc Health Stock Rebounds on Q3 Results as Cash Flow Improves
• Positive Sentiment: BetterHelp generated $32 million of insurance revenue in the quarter. Management also highlighted a target insurance-related run rate of at least $200 million, supporting hopes that the mental-health business can diversify beyond direct consumer payments. Teladoc: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: The company plans to repurchase convertible notes, which could reduce debt-related obligations and signal confidence in its balance-sheet position. Teladoc Targets BetterHelp Insurance Run Rate and Plans Note Repurchase
• Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average likely amplified the rally, but these are trading signals rather than changes to the company’s fundamentals.
• Negative Sentiment: Fourth-quarter revenue guidance of $569 million to $615 million has a midpoint below the $601.7 million consensus estimate. Full-year 2026 EPS guidance of a $0.75 to $0.95 loss also brackets the consensus estimate of a $0.81 loss, underscoring that Teladoc remains unprofitable and growth remains pressured.
• Negative Sentiment: Analyst support remains cautious: Stifel raised its price target to $6.50 but maintained a “hold” rating, implying substantial downside from the recent trading level.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.